Currently, the most likely hypotheses as the cause of Alzheimer’s disease are deposition of amyloid beta peptide in the cerebral cortex and hyperphosphorylation of Tau protein. The diagnosis of Alzheimer’s disease is based on the exclusion of other diseases, behavioral assessments, and blood and imaging tests. Biotechnology has created interesting perspectives for the early detection of Alzheimer’s disease through blood analysis, with special attention to platelets, hemoglobin and vitamin B12. Objective: To evaluate the concentrations of platelets, hemoglobin and vitamin B12 in the blood of older adults with and without dementia of Alzheimer’s disease. Methods: A case-control study involving 120 individuals was conducted, seeking to establish a correlation between changes in platelet, hemoglobin and vitamin B12 concentrations in patients with confirmed AD and in individuals in the inclusion group without AD. The study met the established ethical requirements. Results: Hemoglobin and platelet levels were statistically lower in patients with AD. The biochemical evaluation in AD patient and healthy groups for vitamin B12 showed a decrease in the levels of this compound in patients with AD. Conclusion: We demonstrated the feasibility of the use of blood biomarkers as predictive markers for the diagnosis of AD.

No abstract

No abstract

The hypotheses currently considered the most likely causes of Alzheimer's disease (AD) are amyloid beta peptide deposition in the cerebral cortex and hyperphosphorylation of the Tau protein, with the consequent formation of neurofibrillary tangles. In clinical practice, although not accurate, AD diagnosis is based on the exclusion of other diseases, behavioural assessments and complementary examinations, such as imaging and blood tests. Advances in the field of biotechnology have created exciting prospects for the early detection of AD via biomarker assessment, which is considered a safer and more efficient procedure. Molecules recognised as biomarkers can be expressed in some body fluids, including cerebrospinal fluid, saliva and blood. The presence of amyloid beta peptide and Tau can be confirmed in saliva, which is also an easily and non-invasively collectable material with an accessible cost. The objective was evaluate the concentrations of the t-Tau protein and Ab42 peptide in the saliva of elderly individuals with and without dementia of the AD type Method: The objective of this case-control study, involving a total of 120 individuals, was to analyse whether a correlation exists between variations in the concentrations of the t-Tau and Ab42 biomarkers in the saliva of patients with confirmed AD and individuals in the inclusion group but without AD. We found that t-Tau expression in AD patients is significantly lower than that in individuals without AD, whereas the salivary concentration of Ab42 is higher in patients with AD but not significantly different from that of the group without AD. Conclusion: Thus, we demonstrate the feasibility of using salivary biomarkers as predictive markers for diagnosis of Alzheimer's disease.

No abstract

Objetivo: Classificar diferentes tipos histológicos para carcinoma mamário, do tipo invasivo, com auxílio da imuno-histoquímica. Métodos: Selecionamos 3033 casos positivos, destes, 2433 do tipo invasivo que foram classificados em quatro grupos: Luminal A, luminal B, HER2-eriched e Basal like (triplo negativo). Realizamos um estudo retrospectivo observacional entre os anos de 2011 e 2016Resultados: 2062 (84,4%) dos laudos revisados, foram referentes a CDI SOE, seguido pelos tipos em ordem decrescente: CLI (11,3); carcinoma micropapilar invasivo (1,11%) e os demais tipos com incidência menor que 1 %. Conclusão: Este estudo permitiu a diferenciação histológica e caracterização do perfil IHQ do carcinoma mamário invasivo ocorridos em um período de 6 anos no Distrito Federal.

No abstract

No abstract